Quarterly ResultMay 14, 2026, 04:16 PM
AEON Biopharma Reports Q1 Net Loss of $11.8M; Going Concern Warning
AI Summary
AEON Biopharma, Inc. reported a net loss of $11.8 million for the three months ended March 31, 2026, a significant increase from a $9.1 million net income in the prior year period. The company disclosed substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows. During the quarter, AEON completed the second closing of a PIPE financing, raising $4.2 million, and exchanged $15.0 million in convertible notes with Daewoong for common stock, a new $1.5 million convertible note, and warrants.
Key Highlights
- Net loss for Q1 2026 was $11.8 million, compared to net income of $9.1 million in Q1 2025.
- Basic and diluted net loss per share was $(0.29) in Q1 2026, down from $2.28 net income per share in Q1 2025.
- Company reported substantial doubt about its ability to continue as a going concern.
- Exchanged $15.0 million in convertible notes with Daewoong for common stock, a new $1.5 million convertible note, and warrants.
- Received $4.2 million gross proceeds from the second closing of PIPE financing in January 2026.
- Cash and cash equivalents increased to $6.2 million as of March 31, 2026, from $3.0 million at December 31, 2025.
- Net cash used in operating activities was $2.6 million in Q1 2026, an improvement from $7.9 million in Q1 2025.
- Research and development expenses increased to $2.0 million in Q1 2026 from $0.8 million in Q1 2025.
Price Impact
More from AEON